A regulatory decision in Maharashtra has reopened one of Indian healthcare’s most contentious debates: should homeopathy graduates who complete a short pharmacology course be registered to prescribe modern medicines?
The dispute centres on BHMS practitioners who have completed the Certificate Course in Modern Pharmacology, commonly known as CCMP. Supporters say the pathway recognises additional training and could strengthen access to care. Opponents, led by organisations representing allopathic doctors, argue that it blurs professional boundaries and may expose patients to practitioners whose core undergraduate training is not in modern medicine.
What is the CCMP registration dispute?
The Maharashtra government and the Maharashtra Medical Council have been considering a process under which eligible BHMS-CCMP practitioners could receive a form of registration connected with modern pharmacology. The issue has moved through government meetings, regulatory discussions and court proceedings, with different stakeholders offering sharply conflicting interpretations of what the qualification permits.
The Indian Medical Association’s Maharashtra unit has warned of a statewide shutdown of medical services if registration proceeds before the Bombay High Court decides the matter. The association argues that there is no sufficiently clear statutory framework or standard operating procedure governing dual registration, accountability and the clinical limits of CCMP-qualified practitioners.
Why allopathic doctors are opposing the move
The central objection is not simply about professional territory. Modern-medicine doctors undergo years of undergraduate clinical education, internship and, in many cases, postgraduate training. Their organisations contend that a six-month pharmacology course cannot reproduce the diagnostic, therapeutic and emergency-care training embedded in an MBBS programme.
They also question how responsibility would be determined if a patient experiences an adverse event. Which council would investigate the practitioner? What prescribing limits would apply? Would hospitals, insurers and pharmacies treat the registration as equivalent to an MBBS licence? Unless those questions are answered, critics say the policy risks creating confusion for both patients and regulators.
What supporters of CCMP registration argue
Homeopathy associations and supporters of the policy maintain that qualifying practitioners have completed government-recognised additional instruction and often already serve communities where access to physicians is limited. They argue that a regulated framework is safer than leaving existing cross-practice informal or undefined.
This position raises a practical question for policymakers: if cross-practice already occurs in parts of the healthcare system, should the state prohibit it, narrowly regulate it or formally recognise it? Each option carries consequences for access, standards and accountability.
The patient-safety questions that need clear answers
Patients should be able to understand a practitioner’s original qualification, additional certification and permitted scope of practice before treatment begins. Any final policy would need transparent rules covering disclosure, prescription authority, emergency care, referrals, continuing education, disciplinary jurisdiction and professional indemnity.
The controversy also exposes a deeper problem. Expanding prescribing authority is often presented as a response to shortages, yet the state has separately indicated that it has an adequate number of MBBS doctors for certain service requirements. That apparent contradiction has become a major part of the IMA’s challenge to the policy.
Why the court’s decision matters beyond Maharashtra
The Bombay High Court’s eventual ruling could influence similar debates elsewhere in India about “mixopathy,” bridge courses and the boundaries between recognised systems of medicine. A decision favouring registration may encourage other states to explore comparable pathways. A restrictive decision may reinforce the principle that each medical system must remain within a clearly defined scope.
For patients, the most important outcome is not which professional group wins. It is whether the final rules make qualifications visible, clinical authority unambiguous and accountability enforceable. Healthcare access matters-but access without clarity can create risks that only become visible after something goes wrong.
This article explains an ongoing regulatory and legal dispute. It does not question the lawful practice of homeopathy within its recognised scope, and it does not treat contested claims by either side as established judicial findings.
Sources: The Indian Express; Medical Dialogues; Indian Kanoon court record.